Advanced Solid Malignancies: Clinical Trials

8 trials for Advanced Solid Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 18Terminated 8

Follow Advanced Solid Malignancies: new trials by email Literature Review of Advanced Solid Malignancies trials Research Report on Advanced Solid Malignancies

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
OB318 capsule - Advanced Solid Malignancies
Phase 1TerminatedOneness Biotech Co., Ltd.212020-08-282026-07-10
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Theophylline, Erlotinib - Non-small Cell Lung Cancer, Advanced Solid Malignancies
Phase 1TerminatedAHS Cancer Control Alberta152014-09-012019-05-03
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
AZD1480 Daily, AZD1480 BID - Solid Tumour, Advanced Solid Malignancies
Phase 1TerminatedAstraZeneca472010-11-012013-01-08
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
AZD4547 - Cancer, Advanced Solid Malignancies
Phase 1TerminatedAstraZeneca952009-10-212019-03-15
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
AZD7762, gemcitabine - Cancer, Solid Tumors
Phase 1TerminatedAstraZeneca242009-07-012011-02-07
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
AZD6918, gemcitabine, pemetrexed - Cancer,, Solid Tumors
Phase 1TerminatedAstraZeneca752008-08-012010-12-10
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
BMS-663513 - Advanced Solid Malignancies
Phase 1TerminatedBristol-Myers Squibb452007-09-012009-09-04
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
AZD7762, Irinotecan - Advanced Solid Tumors, Cancer
Phase 1TerminatedAstraZeneca602007-05-012011-02-11

Narrower conditions

Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Diarrhea (1)  ·  Stomach Neoplasms (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Signs and Symptoms (1)  ·  Signs and Symptoms, Digestive (1)

Interventions

3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide (2)  ·  Gemcitabine (2)  ·  AZD4547 (1)  ·  Erlotinib Hydrochloride (1)  ·  Irinotecan (1)  ·  Pemetrexed (1)  ·  Theophylline (1)  ·  urelumab (1)

Sponsors

AstraZeneca (5)  ·  AHS Cancer Control Alberta (1)  ·  Bristol-Myers Squibb (1)  ·  Oneness Biotech Co., Ltd. (1)

Countries

United States (4)  ·  Canada (2)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Peter Langmuir, MD (2)  ·  Becker Hewes, MD (1)  ·  Ching-Liang Ho (1)  ·  Donal Landers, Dr (1)  ·  Jeffrey Infante, MD (1)  ·  Judith Ochs, MD (1)  ·  Kang Yoon-Koo, MD, PhD (1)  ·  Lia Gore, MD (1)  ·  Michael Sawyer, MD (1)  ·  Takashi Seto, MD, PhD (1)